DSIP Results Timeline: What Studies Measured, and When

The short version: the published DSIP literature does not contain a results timeline in the way that phrase is usually meant. There is no set of trials reporting outcomes at week 4, week 8 and week 12 in people. What exists instead is a scattered collection of mostly animal and laboratory studies, each of which picked a measurement window that suited its own model — some measured within minutes of administration, some after a chemical challenge, some after a period of repeated exposure. This page describes those windows as the researchers set them, and labels clearly which findings came from preclinical work.

What a "timeline" means in the DSIP literature

In clinical pharmacology, a results timeline normally comes from repeated measurement of the same endpoint in the same participants at pre-specified visits. That design is what makes statements like "the difference emerged by week 8" meaningful. The DSIP papers verified for this page were not built that way. They were single-model experiments, and the timing of measurement was dictated by the model: an ischaemia-reperfusion protocol forces an acute window, a seizure challenge forces an hours-long window, and a chronic-exposure design forces a longer one.

That distinction matters because a reader looking for "how long DSIP takes to work" is asking a clinical question that the underlying evidence base has not been designed to answer. The honest description is that researchers measured different things at different times in different species, and those measurements do not stack into a human timeline.

Timepoint map of the cited studies

Minutes to hours: the acute-administration studies

Given during reperfusion

The tightest timing constraint in this set comes from infarction work. Researchers reported that a DSIP-like KND peptide reduced brain infarction in C57Bl/6 mice and reduced myocardial infarction in SD rats when it was administered during reperfusion (Biomedicines, 2021). The phrase "during reperfusion" is itself the timeline: the intervention window in that study was the period immediately following restoration of blood flow, not a course of treatment spread over weeks (PMID 33918965). Infarct-size endpoints of this kind are read out after the acute injury has evolved, which is why no "week 4" comparison exists in that design.

After a chemical seizure challenge

A second acute-window design compared anticonvulsant activity. The study reported that valproate and delta-sleep peptide both displayed high efficacy against metaphit-induced audiogenic seizure in rats (Acta Physiologica Hungarica, 2006). In challenge models like this one, the clock starts with the convulsant agent and the observation period is measured in hours, not weeks (PMID 17191662).

In induced acute pancreatitis

The third acute model examined pharmacological efficacy of delta sleep-inducing peptide in experimental acute pancreatitis (Eksperimental'naia i Klinicheskaia Farmakologiia, 2002). Again, the disease model is acute by construction, so the measurement window sat inside the induced episode rather than across a multi-week course (PMID 12109293).

The sleep-model window

Because DSIP is named for sleep, the sleep-model timing question is the one most often asked. The most recent verified paper described Pichia pastoris secreted peptides crossing the blood-brain barrier and assessed DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models (Frontiers in Pharmacology, 2024). Two timing features are worth naming. First, PCPA-induced insomnia is a chemically produced state in mice, so the baseline being corrected is not ordinary human sleep. Second, the study's focus on blood-brain barrier crossing is a pharmacokinetic question — whether the molecule reaches the compartment at all — which sits upstream of any behavioural timeline (PMID 39444618). Nothing in that work translates into a statement about when a person might observe anything.

Longer exposure: repeated-dosing and chronic models

Two entries in the verified set sit further out on the clock. A morphological study described the morphochemical characteristics of rat brain structures after exposure to delta-sleep inducing peptide following long-term amphetamine administration (Morfologiia, 2004). Here the "long-term" descriptor applies to the amphetamine exposure that created the condition under study, and the endpoints were tissue-level rather than behavioural or symptomatic (PMID 15359701). Tissue endpoints are terminal measurements: they are taken once, at sacrifice, which structurally rules out a week-by-week curve.

The remaining paper discussed geroprotective and antidiabetic properties of delta-sleep induced peptide in the context of diabetes mellitus in the elderly (Advances in Gerontology, 2004). Geroprotection is by definition a long-horizon concept, but the indexed record for that paper does not expose a schedule of visits or timed endpoints, so it cannot be converted into a timeline either (PMID 15754961).

Human data: stated plainly

The verified evidence set for this page contains no modern randomised controlled trial in humans with repeated timed endpoints. Most of what is summarised above is preclinical — rodent infarction, rodent seizure, rodent pancreatitis, mouse insomnia, rat brain morphology (PMID 33918965). Several of the papers are older, non-English-language reports indexed by title and abstract only, which limits how much design detail can be verified (PMID 12109293). When an evidence base looks like this, any confident claim about onset in humans — days, weeks, or a specific number of nights — is an extrapolation, not a finding.

This is the central point of the page: thin human data is not the same as negative data, and it is also not permission to fill the gap with a schedule. The correct reading is that the timing question has not been studied in people in a way that would produce an answer.

Why week-by-week tables do not exist for DSIP

• Model-driven windows. Acute injury and challenge models compress measurement into hours by design, as in the reperfusion work (PMID 33918965) and the seizure comparison (PMID 17191662).
• Terminal endpoints. Histological and morphochemical outcomes are measured once, which precludes longitudinal curves (PMID 15359701).
• Induced states, not natural ones. A PCPA-induced insomnia model in mice starts from a pharmacologically produced deficit rather than everyday sleep variability (PMID 39444618).
• Heterogeneous endpoints. Infarct size, seizure response, pancreatic injury, brain morphology and metabolic framing are not interchangeable outcomes and cannot be pooled into one curve (PMID 15754961).

How researchers chose their measurement windows

1. Anchor to the insult. In ischaemia work the anchor was reperfusion itself, which is why administration timing was specified in the title of the study (PMID 33918965).
2. Anchor to the challenge agent. In the audiogenic seizure comparison the anchor was metaphit administration (PMID 17191662).
3. Anchor to delivery. The 2024 work anchored partly on whether secreted peptides crossed the blood-brain barrier before behavioural efficacy was interpreted (PMID 39444618).

Reading a paper's anchor is often more informative than reading its headline result, because the anchor tells a reader what question the timing was built to answer.

Adverse Events and Tolerability: What Studies Report

None of the verified papers summarised here were designed as dedicated safety or tolerability trials with timed adverse-event reporting; they were efficacy-oriented preclinical experiments in defined models, such as the infarction work in mice and rats (PMID 33918965) and the acute pancreatitis model (PMID 12109293). Because of that, the absence of a prominent adverse-event narrative in these titles and abstracts should not be read as a safety finding. A structured human safety timeline for DSIP is not present in this evidence set, and the sleep-model paper likewise focused on delivery and efficacy questions rather than tolerability (PMID 39444618).

What this page does not say

It does not describe onset, duration, week-one expectations, or any schedule of use. It does not convert animal timing into human timing. It does not state doses, because the verified record accessible here does not support dose statements for every claim made, and a dose that cannot be cited is omitted rather than approximated. Delta sleep-inducing peptide is not an approved medicine in the United States, and material described as research-use-only is not intended for human administration.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, symptom or medication.

Related reading

DSIP: what the research literature covers

References

• DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion (Biomedicines, 2021)
• Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models (Frontiers in Pharmacology, 2024)
• Valproate and delta-sleep peptide display high efficacy against metaphit-induced audiogenic seizure in rats (Acta Physiologica Hungarica, 2006)
• [Pharmacological efficacy of delta sleep-inducing peptide in experimental acute pancreatitis] (Eksperimental'naia i Klinicheskaia Farmakologiia, 2002)
• [Morphochemical characteristic of rat brain structures after exposure to delta-sleep inducing peptide following long-term amphetamine administration] (Morfologiia, 2004)
• [Diabetes mellitus in elderly: geroprotective and antidiabetic properties of delta-sleep induced peptide] (Advances in Gerontology, 2004)